FDA approves Pfizer Covid-19 booster shots for Americans ages 65 and older

The third dose will also be available for those considered high risk, however there was not enough evidence for broader authorization

The US Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer and BioNTech Covid-19 vaccine for those ages 65 and older and some high-risk Americans, paving the way for a quick rollout of the shots.

The booster dose is to be administered at least six months after completion of the second dose, and the authorization would include people most susceptible to severe disease and those in jobs that left them at risk, the FDA said.